Emergingby GlyphAmount not disclosed; $1.8B pre-money valuation
Led by 4P Capital
Retro Biosciences
StartupUS1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechDevelops autophagy drugs, iPSC-derived cell therapies and tissue reprogramming aimed at adding ten healthy years. | Develops autophagy drugs, iPSC-derived cell therapies and tissue reprogramming aimed at adding ten healthy years. | retro.bio |
Funding
About
- Source
- retro.bio (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 20, 2026
- Across Glyph
- Retro Biosciences on Companies
Retro Biosciences
Joined in Longevity biotech. Develops autophagy drugs, iPSC-derived cell therapies and tissue reprogramming aimed at adding ten healthy years.
Retro Biosciences
Added in Longevity biotech. Develops autophagy drugs, iPSC-derived cell therapies and tissue reprogramming aimed at adding ten healthy years.